LN229 Cells

LN229 is a human glioblastoma cell line derived from a 60-year-old White female patient with glioblastoma multiforme (GBM), specifically from the right frontal parieto-occipital cortex. Glioblastoma is one of the most aggressive and lethal forms of brain cancer, and LN229 cells are extensively used in research to understand the disease's molecular underpinnings and to develop potential therapeutic strategies. The cells display an epithelial-like morphology and exhibit adherent growth properties, which makes them ideal for in vitro studies. Given their high tumorigenic potential, they readily form tumors when injected into nude mice, making them a robust model for cancer research.

One of the critical characteristics of LN229 cells is the presence of a mutated p53 gene (TP53), with a specific CCT (Pro) to CTT (Leu) mutation at codon 98. This mutation contributes significantly to the cell line's aggressive behavior and resistance to apoptosis. Additionally, LN229 cells have a wild-type PTEN gene, but they exhibit homozygous deletions in the p16 and p14ARF tumor suppressor genes, which are vital regulators of the cell cycle and apoptosis. These genetic alterations make LN229 a valuable model for studying the impact of these mutations on tumor biology and therapeutic resistance.

LN229 cells are particularly useful in apoptosis studies. They undergo apoptosis upon stimulation with Fas ligand, with cell death occurring within 16 hours. Interestingly, while Bcl-2 expression can protect LN229 cells from Fas ligand-induced apoptosis, it only offers limited protection against apoptosis induced by puromycin, a protein synthesis inhibitor. This selective resistance pattern makes LN229 cells a critical model for understanding the molecular mechanisms of apoptosis in glioblastoma and for testing potential apoptosis-modulating therapies. As with all in vitro research models, LN229 cells are not suitable for therapeutic or in vivo applications.